MetaCap

Stoke Therapeutics Cash Flow Statement

NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

24.74+0.79 (+3.30%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Stoke Therapeutics free cash flow

In fiscal 2025, Stoke Therapeutics generated $45.6 million of operating cash flow and spent $670,000 on capital expenditures. That left free cash flow of $44.9 million, a free-cash-flow margin of 24.4% of revenue.

Summary generated from market data by MetaCap's automated system. Methodology

Stoke Therapeutics cash flow statement (annual)

Stoke Therapeutics annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31
Net Income-6.88M-88.98M-104.70M-101.07M-85.81M-52.24M-32.33M-12.52M
Net Income growth (YoY)————————
Depreciation & Amortization1.77M2.18M2.47M1.55M974.00K888.00K450.00K214.00K
Stock-Based Compensation32.24M27.47M25.26M22.85M16.45M5.77M1.92M240.00K
Change in Working Capital-4.94M-31.23M-2.82M43.02M46.00K2.33M-1.13M1.10M
Operating Cash Flow45.59M-86.85M-81.07M-31.87M-66.91M-42.22M-31.05M-10.96M
Capital Expenditures-670.00K-203.00K-1.62M-3.96M-1.20M-1.05M-1.64M-935.00K
Investing Cash Flow-186.81M-107.47M105.95M-45.88M-76.43M-1.05M-1.63M-925.00K
Financing Cash Flow97.39M131.09M53.01M46.41M1.28M108.11M149.76M115.64M
Net Change in Cash-43.84M-63.23M77.89M-31.34M-142.05M64.84M117.07M103.75M
Free Cash Flow44.91M-87.05M-82.68M-35.83M-68.11M-43.27M-32.69M-11.90M

This table shows 8 annual periods of Stoke Therapeutics's cash flow statement, from FY 2025 back to FY 2018, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow STOK's reporting calendar. What is a cash flow statement?

More financial data